Condition: CRC (Colorectal Cancer) · Sponsor: Biotheus Inc.
PM8002 (BNT327) is a bispecific antibody targeting PD-L1 and VEGF. This is a phase II trial to evaluate the efficacy and safety of PM8002 in combination with chemotherapy in first line MSS or MSI-L/pMMR metastatic colorectal cancer.
This description comes directly from the study's public registry record.
Xuelian Xing · +86 18310237570 · xuelian.xing@biontech.com
Always discuss trial participation with your own doctor first.
| Peking University First Hospital | Beijing, Beijing Municipality, China | Recruiting |
| Sun Yat-sen University Cancer Center | Guangzhou, Guangdong, China | Recruiting |
| Guangdong Provincial People's Hospital | Guangzhou, Guangdong, China | Recruiting |
| Harbin Medical University Cancer Hospital | Harbin, Heilongjiang, China | Recruiting |
| Hubei Cancer Hospital | Wuhan, Hubei, China | Recruiting |
| Jilin Cancer Hospital | Changchun, Jilin, China | Recruiting |
| Cancer Hospital of Shandong First Medical University | Jinan, Shandong, China | Recruiting |
| Fudan University Shanghai Cancer Center | Shanghai, Shanghai Municipality, China | Recruiting |
| Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine | Shanghai, Shanghai Municipality, China | Recruiting |
| Sichuan Cancer Hospital | Chengdu, Sichuan, China | Recruiting |
| Zhejiang Cancer Hospital | Hangzhou, Zhejiang, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07133750